- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04186871
Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Subjects With Active Rheumatoid Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
San Juan, Argentina, J5402DIL
- Local Institution - 0066
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1431FWO
- Local Institution - 0065
-
-
Tucuman
-
San Miguel De Tucum, Tucuman, Argentina, T4000AXL
- Local Institution - 0047
-
-
-
-
-
Gent, Belgium, 9000
- Local Institution - 0064
-
Leuven, Belgium, 3000
- Local Institution - 0069
-
-
-
-
-
Brest, France, 29609
- Local Institution - 0075
-
Marseille, France, 13003
- Local Institution - 0070
-
Montpellier Cedex 5, France, 34295
- Local Institution - 0067
-
-
-
-
-
Berlin, Germany, 10117
- Local Institution - 0038
-
Freiburg, Germany, 79106
- Local Institution - 0049
-
Herne, Germany, 44649
- Local Institution - 0074
-
Koln, Germany, 50937
- Local Institution - 0037
-
Munchen, Germany, 80336
- Local Institution - 0051
-
-
-
-
-
San Luis Potosi, Mexico, 78200
- Local Institution - 0114
-
San Luis Potosi, Mexico, 78213
- Local Institution - 0050
-
San Luis Potosi, Mexico, 78240
- Local Institution - 0059
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 44160
- Local Institution - 0060
-
Guadalajara, Jalisco, Mexico, 44650
- Local Institution - 0042
-
Zapopan, Jalisco, Mexico, 45070
- Local Institution - 0113
-
-
Morelos
-
Cuernavaca, Morelos, Mexico, 62290
- Local Institution - 0102
-
-
Yucatan
-
Merida, Yucatan, Mexico, 97000
- Local Institution - 0104
-
-
-
-
-
Groningen, Netherlands, 9713 GZ
- Local Institution - 0004
-
-
-
-
-
Bialystok, Poland, 15-879
- Local Institution - 0094
-
Bydgoszcz, Poland, 85-065
- Local Institution - 0089
-
Bydgoszcz, Poland, 85-168
- Local Institution - 0072
-
Elblag, Poland, 82-300
- Local Institution - 0012
-
Elblag, Poland, 82-300
- Local Institution - 0073
-
Poznan, Poland, 60-773
- Local Institution - 0011
-
Torun, Poland, 87-100
- Local Institution - 0091
-
Warszawa, Poland, 00-660
- Local Institution - 0017
-
Warszawa, Poland, 02-691
- Local Institution - 0033
-
Warszawa, Poland, 02-793
- Local Institution - 0101
-
Warszawa, Poland, 03-291
- Local Institution - 0026
-
-
-
-
-
A Coru, Spain, 15006
- Local Institution - 0028
-
Barcelona, Spain, 08035
- Local Institution - 0036
-
Malaga, Spain, 29010
- Local Institution - 0025
-
Sevilla, Spain, 41010
- Local Institution - 0018
-
Valencia, Spain, 46010
- Local Institution - 0061
-
-
-
-
-
Leeds, United Kingdom, LS7 4SA
- Local Institution - 0076
-
London, United Kingdom, SE1 9RT
- Local Institution - 0058
-
Southampton, United Kingdom, SO16 6YD
- Local Institution - 0052
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Local Institution - 0019
-
-
California
-
Covina, California, United States, 91723
- Local Institution - 0002
-
Encino, California, United States, 91436
- Local Institution - 0024
-
San Diego, California, United States, 92108
- Local Institution - 0034
-
Upland, California, United States, 91786
- Local Institution - 0032
-
-
Florida
-
Brandon, Florida, United States, 33511
- Local Institution
-
DeBary, Florida, United States, 32713
- Local Institution - 0062
-
Hialeah, Florida, United States, 33016
- Local Institution - 0035
-
Jacksonville, Florida, United States, 32209
- Local Institution
-
Plantation, Florida, United States, 33324
- Local Institution - 0029
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30046
- Local Institution - 0009
-
-
Illinois
-
Skokie, Illinois, United States, 60076
- Local Institution - 0014
-
-
Indiana
-
Evansville, Indiana, United States, 47715
- Local Institution
-
-
Louisiana
-
Monroe, Louisiana, United States, 71203
- Local Institution - 0005
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- Local Institution - 0041
-
Grand Blanc, Michigan, United States, 48439
- Local Institution - 0082
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Local Institution - 0096
-
Saint Louis, Missouri, United States, 63141
- Local Institution - 0040
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68516
- Local Institution - 0056
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
- Local Institution - 0007
-
-
New York
-
Manhasset, New York, United States, 11030
- Local Institution
-
New York, New York, United States, 10016
- Local Institution
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Local Institution - 0008
-
Salisbury, North Carolina, United States, 28144
- Local Institution - 0006
-
-
North Dakota
-
Minot, North Dakota, United States, 58701
- Local Institution
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 79112
- Local Institution - 0022
-
Oklahoma City, Oklahoma, United States, 73103-2433
- Local Institution - 0023
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Local Institution - 0010
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Local Institution - 0045
-
Summerville, South Carolina, United States, 29486
- Local Institution - 0021
-
-
Tennessee
-
Jackson, Tennessee, United States, 38305
- Local Institution - 0079
-
Memphis, Tennessee, United States, 38119
- Local Institution - 0001
-
-
Texas
-
Colleyville, Texas, United States, 76034
- Local Institution - 0092
-
Dallas, Texas, United States, 75231
- Local Institution
-
Houston, Texas, United States, 77084
- Local Institution - 0063
-
Mesquite, Texas, United States, 75150
- Local Institution - 0016
-
Plano, Texas, United States, 75024
- Local Institution - 0030
-
San Antonio, Texas, United States, 78215
- Local Institution - 0031
-
Waco, Texas, United States, 76710
- Local Institution
-
-
Washington
-
Spokane, Washington, United States, 99204
- Local Institution - 0083
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Sub-study for Systemic Lupus Erythematosus (SLE)
- Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification
- Diagnosed with SLE more than 24 weeks before screening visit
Sub-study for primary Sjögren's Syndrome (pSS)
- Moderate to severe pSS, meeting ACR-EULAR classification criteria
Sub-study for active Rheumatoid Arthritis (RA)
- Moderate to severe adult-onset RA
- ACR global functional status class I to III
Women and men must agree to follow instructions for methods of contraception.
Exclusion Criteria:
Sub-study for SLE
- Certain other autoimmune diseases and overlap syndromes
Sub-study for pSS
- Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions
Sub-study for RA
- Diagnosis with juvenile arthritis or idiopathic arthritis before age 16
For all sub-studies:
- History of any significant drug allergy
- Active infection, significant concurrent medical condition, or clinically significant abnormalities
Other protocol defined inclusion/exclusion criteria could apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Systemic Lupus Erythematosus (SLE): branebrutinib
|
Specified dose on specified days
|
Placebo Comparator: SLE: placebo
|
Specified dose on specified days
|
Experimental: Primary Sjögren's Syndrome (pSS): branebrutinib
|
Specified dose on specified days
|
Placebo Comparator: pSS: placebo
|
Specified dose on specified days
|
Experimental: Rheumatoid Arthritis (RA): branebrutinib followed by abatacept
|
Specified dose on specified days
Specified dose on specified days
|
Placebo Comparator: RA: placebo followed by abatacept
|
Specified dose on specified days
Specified dose on specified days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE
Time Frame: Week 24
|
mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index |
Week 24
|
The Percent of Participants With Composite Response at Week 24 - pSS
Time Frame: Week 24
|
Composite response is defined as the percent of participants with at least 3 of the following at Week 24:
|
Week 24
|
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA
Time Frame: Week 12
|
ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria:
Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in SLEDAI-2K Score at Week 24 - SLE
Time Frame: Week 24
|
The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 24
|
Percent of Participants With BICLA Response at Week 24 - SLE
Time Frame: Week 24
|
BILAG-based composite lupus assessment (BICLA) response is defined as:
BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 24
|
Change From Baseline in DAS28-CRP at Week 12 - RA
Time Frame: Week 12
|
The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: < 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity > 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 12
|
Change From Baseline in DAS28-ESR at Week 12 - RA
Time Frame: Week 12
|
The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures:
DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: < 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity > 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 12
|
Change From Baseline in SDAI at Week 12- RA
Time Frame: Week 12
|
The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result.
Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).
|
Week 12
|
Change From Baseline in CDAI at Week 12 - RA
Time Frame: Week 12
|
The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity |
Week 12
|
Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA
Time Frame: Week 12
|
ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria:
Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 12
|
Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA
Time Frame: Week 12
|
ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria:
Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. |
Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Bristol-Myers Squibb, Bristol-Myers Squibb
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Eye Diseases
- Disease
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Stomatognathic Diseases
- Mouth Diseases
- Lacrimal Apparatus Diseases
- Xerostomia
- Salivary Gland Diseases
- Dry Eye Syndromes
- Syndrome
- Arthritis
- Arthritis, Rheumatoid
- Lupus Erythematosus, Systemic
- Autoimmune Diseases
- Sjogren's Syndrome
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Immune Checkpoint Inhibitors
- Abatacept
- Branebrutinib
Other Study ID Numbers
- IM014-029
- 2019-002205-22 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on branebrutinib
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisAustralia
-
Bristol-Myers SquibbCompletedDermatitis, AtopicGermany, Australia, Poland, Canada, Austria, United States, Spain
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States
-
Bristol-Myers SquibbCompletedRheumatoid ArthritisUnited States
-
Bristol-Myers SquibbCompleted